Zacks Research Issues Pessimistic Forecast for CL Earnings

Colgate-Palmolive (NYSE:CL) – Research analysts at Zacks Research cut their Q2 2025 EPS estimates for Colgate-Palmolive in a note issued to investors on Thursday, May 8th. Zacks Research analyst R. Lohia now anticipates that the company will earn $0.89 per share for the quarter, down from their prior forecast of $0.94. The consensus estimate for Colgate-Palmolive’s current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Colgate-Palmolive’s Q3 2025 earnings at $0.91 EPS, Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $3.65 EPS, Q2 2026 earnings at $0.95 EPS, Q3 2026 earnings at $0.97 EPS, Q4 2026 earnings at $1.01 EPS, FY2026 earnings at $3.90 EPS, Q1 2027 earnings at $1.03 EPS and FY2027 earnings at $4.15 EPS.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, April 25th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.05. Colgate-Palmolive had a net margin of 14.38% and a return on equity of 477.77%. The company had revenue of $4.91 billion during the quarter, compared to the consensus estimate of $4.92 billion. During the same period in the prior year, the firm earned $0.86 earnings per share. Colgate-Palmolive’s revenue was down 3.0% on a year-over-year basis.

A number of other equities analysts also recently issued reports on the stock. Citigroup increased their price target on shares of Colgate-Palmolive from $103.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, April 28th. Raymond James restated an “outperform” rating and issued a $105.00 price objective (down previously from $110.00) on shares of Colgate-Palmolive in a report on Monday, February 3rd. UBS Group upped their price objective on shares of Colgate-Palmolive from $105.00 to $109.00 and gave the stock a “buy” rating in a report on Thursday, April 17th. Stifel Nicolaus cut their price objective on shares of Colgate-Palmolive from $95.00 to $93.00 and set a “hold” rating on the stock in a report on Monday, February 3rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Colgate-Palmolive from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Monday, April 28th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Colgate-Palmolive presently has a consensus rating of “Hold” and a consensus target price of $102.39.

Colgate-Palmolive Price Performance

CL stock opened at $87.88 on Monday. Colgate-Palmolive has a 1 year low of $85.32 and a 1 year high of $109.30. The company has a market cap of $71.22 billion, a P/E ratio of 24.97, a PEG ratio of 4.20 and a beta of 0.39. The firm has a 50-day moving average of $92.05 and a 200 day moving average of $91.40. The company has a debt-to-equity ratio of 13.40, a current ratio of 0.92 and a quick ratio of 0.58.

Institutional Investors Weigh In On Colgate-Palmolive

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Colgate-Palmolive by 0.6% in the first quarter. Vanguard Group Inc. now owns 81,758,257 shares of the company’s stock worth $7,660,749,000 after purchasing an additional 455,198 shares during the last quarter. Geode Capital Management LLC raised its position in Colgate-Palmolive by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 20,518,014 shares of the company’s stock worth $1,868,723,000 after acquiring an additional 324,683 shares during the period. Norges Bank bought a new position in Colgate-Palmolive in the fourth quarter worth approximately $912,375,000. Northern Trust Corp raised its position in Colgate-Palmolive by 11.7% in the fourth quarter. Northern Trust Corp now owns 9,497,819 shares of the company’s stock worth $863,447,000 after acquiring an additional 993,328 shares during the period. Finally, Amundi raised its position in Colgate-Palmolive by 12.8% in the fourth quarter. Amundi now owns 9,200,144 shares of the company’s stock worth $806,015,000 after acquiring an additional 1,040,604 shares during the period. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive declared that its board has authorized a stock buyback program on Thursday, March 20th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Colgate-Palmolive Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Thursday, April 17th will be issued a $0.52 dividend. The ex-dividend date is Thursday, April 17th. This represents a $2.08 annualized dividend and a yield of 2.37%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.50. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 58.76%.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.